New combo attack on aggressive breast cancer shows promise in early trial
NCT ID NCT06682195
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for women with triple-negative breast cancer. About 35 participants will receive the combination, then undergo surgery. The main goal is to see how many have no cancer cells left in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Toripalimab (an immunotherapy drug) combined with chemotherapy drugs epirubicin, cyclophosphamide, and albumin-bound paclitaxel
- What this could lead to
- If successful, this could lead to a more effective treatment approach for triple-negative breast cancer before surgery, potentially improving long-term outcomes.
- What could go wrong
- This is a small, early-phase trial with only 35 participants and no comparison group. The combination may cause side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, China
-
Jinhua Municipal Central Hospital
RECRUITINGJinhua, China
-
Nanchang People's Hospital
NOT_YET_RECRUITINGNanchang, Jiangxi, China
-
Nantong First People's Hospital
RECRUITINGNantong, China
-
Shanxi Provincial Cancer Hospital
NOT_YET_RECRUITINGShanxi, China
-
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, China
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
-
The First Affiliated Hospital of Zhejiang University
RECRUITINGHangzhou, China
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, China
-
The Second Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITINGXi'an, China
-
Xinjiang Medical University Affiliated Cancer Hospital
NOT_YET_RECRUITINGXinjiang, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, China
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers